December 7, 2011Open Access
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
José Baselga
Université Paris-Sud
Javier Cortés
Villa Maria Hospital
S
Sung‐Bae Kim
Ulsan College
Journals
New England Journal of Medicine
Actions
Institutions
Harvard University
Massachusetts General Hospital
Seoul National University
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...